資源描述：
《培美曲塞、多西他賽聯(lián)合順鉑一線治療晚期肺腺癌的療效觀察.doc》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、培美Illi塞、多西他賽聯(lián)合順鉗一線治療晚期肺腺癌的療效觀察［摘要］目的：比較培美曲塞(PEM)聯(lián)合順鉗(DDP)與多西他賽(DOC)聯(lián)合DDP治療晚期肺腺癌的臨床療效及毒性反應(yīng)。方法：將44例晚期肺腺癌(IIIB?IV期)患者隨機分為培美曲塞加順鉗組(PC組)和多西他賽加順鉗組(DC組),每組22例。PC組,PEM500mg/m2+生理鹽水100ml,靜滴10?30min,第1天；DC組,D0C75mg/m2+生理鹽水250ml靜滴1h,第1天。兩紐DDP均為25mg/m2,第1?3天給藥；每21天重
2、復(fù)。治療2個周期后評價療效，治療期間觀察不良反應(yīng)。結(jié)果：PC組總有效率為45.5%,屮位無進(jìn)展時間5.5個月；DC組總有效率為40.9%,中位無進(jìn)展時間4.8個月。兩纟R比較差異均無統(tǒng)計學(xué)意義(均P>0.05)。PC組骨箭抑制、胃腸道反應(yīng)、肝腎功能損害等毒性反應(yīng)顯著低于DC組(均P<0.05)。結(jié)論：培美曲塞聯(lián)合順鉗治療晚期非小細(xì)胞肺癌的療效與多西他賽加順鉗的療效相當(dāng)，但毒性反應(yīng)明顯減少，可作為晩期肺腺癌患考的一線治療用藥。［關(guān)鍵詞］肺腺癌；一線化療；培美曲塞；多西他賽；順鉗［中圖分類號］R734.2［
3、文獻(xiàn)標(biāo)識碼］A［文章編號］1673-7210(2011)11(c)-078-03ObservationofcurativeeffectonPemetrexedorDocetaxelplusCisplatininthefirst-linetreatmentofpatientswithlungadenocarcinomaCHENShouhua,YAOWeidong,GUHongbingDcpartmentofMedicalOncology,NantongTumorHospital,JiangsuProvin
4、ce,Nantong226361,China［Abstract］Objective:ToobservetheefficacyandtoxicityofPemetrexedorDocetaxelplusCisplatininthefirst-linetherapyofpatientswithlungadenocarcinoma.Methods:44patientswithlatestagelungadenocarcinoma(thestageofIIIB-IV)wereenrolledintothisst
5、udy.ThesepatientsweredividedintoPCgroup(PemetrexedplusCisplatin)andDCgroup(DocetaxelplusCisplatin),with22casesineachgroup,groupPC:Pemetrexed500mg/m2plusnormalsaline100ml,10-30minivgtt,inthefirstday;DCgroup:Docetaxel75mg/m2plusnormalsaline250ml,1hivgtt,in
6、thefirstday.BothgroupsweregivenCisplatin25mg/m2ivgtt,dl-3.Thetreatmentwouldberepeatedevery21days?Theefficacyandtoxicityofpatientsafterreceivingtwocycleswillbeevaluated.ResuIts:Theoverallresponseratewas45.5%inPCgroupand40.9%inDCgroup.Theaveragetimeforprog
7、ressivediseasewas5.5monthsinPCgroupond4.8monthsinDCgroup.Nosignificantstatisticaldifferencesintheoverallresponseratesandtheaveragetimeforprogressivewerefoundbetweenthetwogroups(P>0.05).Thesideeffectsofmyelosuppression,gastrointestinaldisorders,toxityof1i
8、verandkidneyandhematologictoxicitiesinPCgroupwerelessandslighterthanDCgroup(P<0.05).Conclusion:PemetrexedplusCisplatinhasthesameactivityasDocetaxelplusCisplatininthetreatmentofpatientswithlungadenocarcinoma,butthetoxicitie
